Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

$846,595 $661,982

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of Projected GAAP Basic Income per Common Share

to Basic Adjusted Income Per Common Share Guidance

(Unaudited)

Twelve Months Twelve Months

Ended Ended

December 31, 2008 December 31, 2009

Projected GAAP basic income per common

share $4.41 - $4.51 $4.95 - $5.05

Amortization of current intangibles $1.48 - $1.48 $1.36 - $1.36

Accelerated depreciation adjustment-

CIMA $0.10 - $0.10 $0.09 - $0.09

Accelerated depreciation adjustment-

Mitry-Mory $0.10 - $0.10 $0.24 - $0.24

Cost of goods sold adjustments $0.38 - $0.38 $- - $-

Research and development adjustments $0.12 - $0.12 $- - $-

Selling, general and administrative

adjustments $0.44 - $0.44 $- - $-

Settlement reserve adjustments $0.11 - $0.11 $- - $-

In-process research and development

adjustment $0.15 - $0.15 $- - $-

Restructuring adjustments $0.12 - $0.12 $0.07 - $0.07

Interest expense adjustment $0.17 - $0.17 $- - $-

Interest expense adjustment for

APB 14-1 $- - $- $0.63 - $0.63

Tax effect of pre-tax adjustments at

the applicable tax rates $(2.38)- $(2.38) $(0.84)- $(0.84)

Basic adjusted income per common share

guidance $5.20 - $5.30 $6.50 - $6.6
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and BANGALORE, India , July ... profiling company that uses next generation sequencing technology to ... Scott A. Storrer as chief executive officer. In ... will be responsible for all strategy, business expansion and ... who has served as Strand,s chairman and CEO since ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan contest will ... barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 ... US$15,000 and a period of expert mentorship from a senior industry figure drawn from ...
(Date:7/1/2015)... YORK , July 1, 2015  UCB, ... G ), a global leader in designing, transforming, ... Aecus Innovation Award in recognition of their close ... efficiencies in UCB,s global business services (GBS) finance ... service providers and clients that work together effectively ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... (AFM) is hosting a webinar to provide advanced scientific research into new classes ... bio science and energy. Touted as 'the wonder material of the 21st ...
Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
... recent decision to pull Pfizer Cox-2 inhibitor Bextra from the marketplace ... up in the Merck Vioxx dilemma months ago and its stock ... $25 per share in February. It has recently moved up to ... about 30 percent in the last 12 months. , ,Though Pfizer ...
... Controls Inc., which makes auto parts and facility-control systems, reported ... on sales of $7.1 billion. , ,That's up from $158 ... quarter a year ago. , ,"We have faced unprecedented challenges ... result, have accelerated actions to help ensure our company's competitiveness," ...
... Accountability Act privacy deadline two years ago, the security ... compliance and many companies may not yet be compliant. ... HIPAA rule involves too many software protocols throughout the healthcare ... admitting that it can't comply with a guideline moves a ...
Cached Biology Technology:Why are new drugs failing? 2Why are new drugs failing? 3Why are new drugs failing? 4Why are new drugs failing? 5Why are new drugs failing? 6As HIPAA deadline passes even the unprepared are safe for now 2As HIPAA deadline passes even the unprepared are safe for now 3
(Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... papers appearing in the prestigioous journal Science ... Besansky, a professor of biological sciences and a member ... University of Notre Dame, provided evidence that Anopheles gambiae, ... the malaria parasite in Sub-Saharan Africa, is evolving into ...
... a mouse that can run on a treadmill twice ... supply of acetylcholine, the neurotransmitter essential for muscle contraction., ... could lead to new treatments for neuromuscular disorders such ... fail to reach the muscles, said Randy Blakely, Ph.D., ...
... While Yellowstone,s celebrated bison may be among the ... habits and increasing numbers have raised questions about the ... the National Park Service has partnered with Syracuse University ... climate change and herbivores on the park,s grasslands over ...
Cached Biology News:New study examines immunity in emerging species of a major mosquito carrer of malaria 2Boosting supply of key brain chemical reduces fatigue in mice 2SU biologist partners with National Park Service to study bison grazing in Yellowstone 2SU biologist partners with National Park Service to study bison grazing in Yellowstone 3
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... PP2A1, purified Formulation: 50mM ... 0.02% Brij-35, 0.2mM PMSF, 1mM ... glycerol. Properites: PP2A1 (Protein Phosphatase ... DEAE-Sephadex, ammonium sulfate precipitation, QSepharose,amino-hexyl ...
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
Biology Products: